Navigation Links
2-day results predict ultimate response to therapy in chronic hepatitis C
Date:3/20/2009

A new study suggests that previously noted low rates of successful hepatitis C virus (HCV) therapy in African Americans are in large part due to very early differences in the antiviral activity induced by interferon. The study is published in the April 15 issue of the Journal of Infectious Diseases, now available online.

More than 3 million Americans are infected with HCV, and in some countries more than 10 percent of the population is infected. Chronic HCV infection is the leading cause of liver failure worldwide. Response to standard therapy with peginterferon and ribavirin varies widely. Those infected with one strain of the virusgenotype 1are the least likely to have a successful response to therapy, known as a sustained virological response (SVR). About one-half of patients infected with genotype 1 do not achieve SVR.

Studies have shown that African Americans have consistently lower rates of SVR to interferon-based therapy, compared to Caucasian Americans. A recent study of those with chronic genotype 1 HCV infection found that only 28 percent of African American patients attained SVR, compared with 52 percent in Caucasian Americans. This new study shows that the variation in therapy responsiveness between African Americans and Caucasian Americans can be partly explained by differences in viral response noted as early as one to two days after the first dose of peginterferon.

The study, conducted by a collaborative group of eight medical centers throughout the United States, monitored 341 patients with chronic HCV, genotype 1, who underwent therapy with peginterferon and ribavirin for at least 24 weeks. It focused on response rates to interferon therapy within the first 28 days of therapy, noting viral factors such as HCV RNA levels and host factors such as race, gender, and weight.

Results showed that HCV RNA levels decreased in almost all patients, and that the degree and pattern of decrease, as expected, was different between African and Caucasian Americans. Most important was the new finding that these differences were statistically significant by day 2 of treatment, and that this early viral kinetic measurement was a reliable predictor of ultimate SVR rates. After 28 days of treatment, 22 percent of Caucasian Americans, but only 12 percent of African Americans, were HCV RNA negative.

These findings are particularly important because they point toward the presence of some block or defect in the immediate antiviral response of those who do not respond to therapy. As the authors summarize, "The underlying cause of virological non-response and the reasons why it is more common among African Americans than Caucasian Americans are not clear. [But] the current analyses demonstrated that these differences are fundamentally biologic and become apparent within 24 to 48 hours of starting therapy." As a next step, future research should focus on these host biologic factors that are induced by interferon in an attempt to improve therapy response rates.

In an accompanying editorial, Andrew W. Tai, MD, PhD, and Raymond T. Chung, MD, of Massachusetts General Hospital agree that the findings will prove vital for future research into HCV, remarking, "[this study] demonstrates that the low rates of SVR in African American patients in response to IFN-based therapy appear to result, in large part, from impaired early viral kinetics. Further studies are necessary to uncover the relevant mechanisms that underlie this defect in IFN signaling with the hope that such mechanisms can be manipulated to restore interferon responsiveness in the otherwise nonresponsive host."


'/>"/>

Contact: Steve Baragona
sbaragona@idsociety.org
703-299-0412
Infectious Diseases Society of America
Source:Eurekalert

Related medicine news :

1. Haemacure Reports Third Quarter 2007 Results
2. Brooke Franchise Corporation Announces Selected July Results
3. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
4. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
5. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
6. NBTY Announces Preliminary Unaudited Net Sales Results For August 2007
7. Martek Announces Third Quarter 2007 Financial Results
8. MDS Reports Third Quarter 2007 Results
9. Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007
10. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
11. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... “Wounded Woman Be Ye Healed-Passing ... Ye Healed-Passing On A Legacy” is the creation of published author, Desiree M Webb, ... grief ministry. She has been happily married to her husband, Paul, for over ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ogden Clinic, the ... - centric payment system, to expand its focus on patient care by providing ... experience. , “At Ogden Clinic, we are working to become a different ...
(Date:3/23/2017)... ... March 23, 2017 , ... “The Trainer”: an electrifying ... author, Scotty, a fiction writer with an active imagination and an enthusiasm for action ... follows the tale of Wild Bill Hart, who sat looking at the thirty-three notches ...
(Date:3/23/2017)... ... 23, 2017 , ... Vortex Biosciences, provider of circulating tumor ... circulating tumor cells using microfluidic western blotting” in Nature Communications on March 23rd. ... to capture CTCs and a microfluidic single-CTC resolution Western blot from ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... of the first issue of its companion print magazine. The new magazine, scheduled ... surgery thanks to information provided by board-certified doctors from across the country. , ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... March 22, 2017  ImaginAb Inc. today announced the appointment of ... Joseph Limber , chairman of ImaginAb, said "At ImaginAb we ... that is directly relevant to our business, particularly in commercializing and ... with his leadership, we can realize our potential." ... Mr. Coombs is a recognized industry ...
(Date:3/22/2017)... , 22. März 2017   VWR ... weltweit tätige Anbieter von Produkten und Dienstleistungen ... Erwerb von EPL Archives Inc. bekannt, eines ... Kunden im kompletten Zyklus regulierter Forschung, Entwicklung ... Proben, Speicherung von Dokumenten und Zusatzdienstleistungen zur ...
(Date:3/22/2017)... 2017 Research and Markets has announced the ... - Industry Forecast to 2025" report to their offering. ... The Global Pharmaceutical ... 7.1% over the next decade to reach approximately $129.81 billion by ... forecasts for all the given segments on global as well as ...
Breaking Medicine Technology: